
- /
- Supported exchanges
- / US
- / VTGN.NASDAQ
VistaGen Therapeutics Inc (VTGN NASDAQ) stock market data APIs
VistaGen Therapeutics Inc Financial Data Overview
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline comprises of Fasedienol(PH94B), an investigational pherine nasal spray for the treatment of anxiety in adults with social anxiety disorder which is in Phase III clinical trial; and Itruvone(PH10), an odorless synthetic investigational neuroactive pherine nasal spray for the treatment of major depressive disorder which is in Phase II clinical trial. It also develops PH80, an odorless and tasteless synthetic investigational pherine nasal spray with a novel for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders that is in Phase II clinical trial; PH15, an investigational pherine nasal spray with a novel for the treatment to improve cognitive impairment caused by mental fatigue and potentially other disorders that is in Phase II clinical trial; and PH284, an odorless and tasteless synthetic investigational pherine nasal spray with a novel for the treatments of the loss of appetite associated with chronic disorders, such as cancer, heart disease, as well as cachexia that is in Phase II clinical trial. In addition, the company is developing an oral candidate, AV-101, an Oral NMDR glycine site antagonist for the treatment of depression and neurological disorders that is in phase I clinical trial. Further, its clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get VistaGen Therapeutics Inc data using free add-ons & libraries
Get VistaGen Therapeutics Inc Fundamental Data
VistaGen Therapeutics Inc Fundamental data includes:
- Net Revenue: 486 K
- EBITDA: -55 823 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-31
- EPS/Forecast: -0.49
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
VistaGen Therapeutics Inc News

Stifel reiterates buy rating on VistaGen stock amid clinical progress
Stifel maintained its buy rating and $12.00 price target on VistaGen Therapeutics (NASDAQ:VTGN) following the company’s fiscal year 2025 update. Currently trading at $2.16, the stock appears underva...


Vistagen targets transformative SAD drug approval with top-line PALISADE-3 data in Q4 2025 while advancing differentiated neuroscience pipeline
Earnings Call Insights: Vistagen Therapeutics (VTGN) Q4 2025 MANAGEMENT VIEW * President and CEO Shawn K. Singh highlighted that Vistagen is advancing a pipeline of five clinical-stage pherine pro...

Earnings call transcript: Vistagen's focus on innovation amid rising expenses Q1 2025
Vistagen Therapeutics held its Q1 2025 earnings call, highlighting increased research and development expenses and a strategic focus on its innovative pipeline. Despite a net loss of $51.4 million, th...

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
Topline results of PALISADE-3 Phase 3 Trial of fasedienol for acute treatment of social anxiety disorder expected in the fourth quarter of this year PALISADE-4 Phase 3 Trial topline results expected ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.